10-Q: STAAR Surgical Reports 7% Revenue Increase in Second Quarter 2024

STAAR Surgical Company announced a 7% increase in net sales for the second quarter of 2024, driven primarily by growth in ICL sales.

Summary

• STAAR Surgical Company reported a 7% increase in net sales for the three months ended June 28, 2024, reaching $99.0 million compared to $92.3 million in the same period of 2023.
• The increase in net sales was primarily due to a $6.3 million rise in ICL sales.
• For the six months ended June 28, 2024, net sales increased by 6% to $176.4 million, up from $165.8 million in the first half of 2023.
• ICL sales for the first half of 2024 increased by $12.8 million, while other product sales decreased by $2.3 million.
• Gross profit margin improved to 79.2% for the three months ended June 28, 2024, compared to 76.6% in the same period of 2023.
• Gross profit margin for the six months ended June 28, 2024, was 79.1%, up from 77.4% in the first half of 2023.
• Net income for the three months ended June 28, 2024, was $7.4 million, or $0.15 per diluted share, compared to $6.1 million, or $0.12 per diluted share, in the same period of 2023.
• Net income for the six months ended June 28, 2024, was $4.0 million, or $0.08 per diluted share, compared to $8.8 million, or $0.18 per diluted share, in the first half of 2023.
• The company's cash and cash equivalents totaled $192.8 million as of June 28, 2024, compared to $183.0 million at the end of 2023.

Sentiment

Score: 6

Explanation: The document shows positive revenue growth and improved gross margins, but also highlights increased expenses and a decrease in net income for the first half of the year. The sentiment is moderately positive, with some concerns about profitability.

Positives

• The company experienced a 7% increase in net sales for the second quarter of 2024, driven by strong ICL sales.
• Gross profit margins improved to 79.2% for the quarter and 79.1% for the first half of the year.
• The company's cash position remains strong with $192.8 million in cash and cash equivalents.
• ICL sales saw growth across all regions, including APAC, EMEA, and the Americas.
• The company has a strong focus on its ICL product line, which is driving revenue growth.

Negatives

• Other product sales decreased significantly, primarily due to the phase-out of cataract IOLs.
• Foreign currency fluctuations negatively impacted net sales by $1.4 million in the second quarter and $2.3 million in the first half of 2024.
• Net income for the six months ended June 28, 2024, was lower than the same period in 2023.
• General and administrative expenses increased by 30.6% for the three months ended June 28, 2024, and 29.5% for the six months ended June 28, 2024.
• Selling and marketing expenses decreased by 10.7% for the three months ended June 28, 2024, and 5.3% for the six months ended June 28, 2024.

Risks

• The company is subject to risks related to foreign currency fluctuations, which can impact sales and profitability.
• The company's reliance on a single vendor for a significant portion of its accounts payable poses a potential risk.
• The company faces risks related to legal proceedings and claims that may arise in the normal course of business.
• The company's future effective income tax rate depends on various factors, such as changes in tax laws and the geographic composition of pre-tax income.
• The company's success is subject to many factors that are beyond its control, as detailed in their annual report.

Future Outlook

The company intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. The company's growth strategy includes making its complete ICL product line available in existing geographic markets and expanding into new markets. The company is focused on driving awareness of the ICL procedure and providing surgeon training and education.

Management Comments

• Management believes that there have been no significant changes during the six months ended June 28, 2024 to the items that we disclosed as our critical accounting estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 29, 2023.
• Management believes that the company's sources of liquidity will be sufficient to meet its anticipated cash needs for at least 12 months from the issuance date of the financial statements.

Industry Context

The company operates in the ophthalmic surgical product market, specifically focusing on implantable lenses for refractive surgery. The company's growth is driven by the increasing demand for vision correction procedures and the adoption of its ICL technology.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, STAAR Surgical's focus on ICLs positions it in a niche market within the broader ophthalmic surgical industry.
• Companies like Alcon and Johnson & Johnson Vision are major players in the broader ophthalmic market, but they have a more diverse product portfolio including contact lenses, cataract surgery products, and other vision care solutions.
• STAAR's growth in ICL sales suggests a strong market position in the phakic IOL segment, which is a smaller but growing part of the overall refractive surgery market.
• The company's gross margin of around 79% is relatively high, indicating a premium product offering and efficient cost management compared to some other medical device companies.

Legal Proceedings

• The company is involved in various legal proceedings and other matters arising in the normal course of business, but does not believe any of the claims known is likely to have a material adverse effect on the company's financial condition or results of operations.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth and improved gross margins, but concerned about the decrease in net income for the first half of the year.
• Employees may be impacted by changes in compensation and benefits.
• Customers will continue to benefit from the company's products and services.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors will be interested in the company's financial stability and ability to meet its obligations.

Next Steps

• The company will continue to focus on growing its ICL business and expanding into new markets.
• The company will monitor its financial performance and adjust its strategies as needed.
• The company will continue to disclose material non-public information on its website.

Key Dates

Keywords

ICL, Implantable Collamer Lenses, Ophthalmic Surgery, Refractive Surgery, Net Sales, Gross Profit, Financial Results, Surgical Products, STAAR Surgical, Medical Devices